European Primary Care Cardiovascular Society

Surprising result: Very high levels of HDL-c are associated with increased risk of CV events

Aug. 30, 2018 - Dr. Mark Philip Allard-Ratick, Atlanta, GA, USA

Association higher healthy diet score and lower risk of mortality and CV events across the globe

Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

CV safety with weight loss agent in high-risk overweight or obese patients

Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK

Hypertension - Can we agree on diagnostic and therapeutic thresholds?

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Prof. Richard McManus, prof. Richard Hobbs and prof. Christos Lionis

Complexities of managing heart failure

Mar. 16, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Clare Taylor, Dr. Nuria Farré and Dr. Frans Rutten
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Lipids and food

July 11, 2018 - Prof. David Marais - Cape Town, South Africa

The cardiovascular challenge for primary care in diabetes

July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Spain - EPCCS Introduction

June 19, 2018

Lower Extremity Artery Disease: a neglected major CV disease: Diagnosis and clinical management in primary care

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Rafel Ramos (Girona, Spain)

Lipid lowering: the evidence, the guidelines, the clinical reality

Mar. 17, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Monika Hollander, prof. Frank Visseren, dr. Jan Oltrogge

Management of CV risk that comes with T2DM in light of novel treatment options

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Pharmacist intervention in American 'black barbershops' effective at lowering BP

Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

Striking results for weight reduction in T2DM in primary care based program

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 20, 2017 - AHA 2017 - Anaheim, CA, USA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

Prevention of atherosclerotic CV events with cholesterol absorption inhibitor in older patients

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.

2nd edition of physical activity guidelines for Americans released by U.S. Department of Health & Human Services

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 The Federal physical activity guidance stresses the importance and feasibility of incorporating more physical activity in daily life for all ages, and highlights all preventive benefits of physical activity.

No reduction in major CVD events with omega-3s or vitamin D in primary prevention cohort

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 The VITAL trial tested the effect of vitamin D and/or omega-3 supplementation on CVD and cancer outcomes in a large primary prevention cohort, and found few benefits of either product.

Improved quality of life but not CV events with yoga-based cardiac rehabilitation post-MI

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 Yoga-CaRe is safe, feasible and significantly improves quality of life and return to pre-infarct daily activities. The per-protocol analysis suggests that yoga does lower CV events in adherent patients.

Lower risk of ischemic events with triglyceride-lowering agent in hypertriglyceridemic patients on statins

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 In the randomized REDUCE-IT trial, daily treatment with icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowered CV events in primary and secondary prevention of hypertriglyceridemic patients.

More focus on personalized risk assessment in updated AHA/ACC cholesterol guidelines

AHA 2018 – Chicago, IL, USA

Nov. 13, 2018 - news

AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.

Mortality and CV events not reduced with antihypertensive treatment in low-risk patients with mild hypertension

Nov. 9, 2018 - Sheppard JP et al. - JAMA Intern Med 2018

In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.

Intensive lifestyle intervention program associated with reduced CV risk in overweight/obese adults

Nov. 9, 2018 - Salas-Salvadó J et al. - Diabetes Care 2018

In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.

Novel exercise parameter inversely associated with risk of HF and mortality

Nov. 5, 2018 - Al Rifai M et al. - Heart 2018

In a large cohort study, pulse pressure stress index (P2SI) was inversely associated with risk of HF and all-cause mortality in individuals with suspected CAD.

Possible negative impact of prolonged sitting on vascular health

Nov. 1, 2018 - Credeur DP et al. - Am J Cardiol 2018

Several measurements in a small sample of healthy individuals suggest that prolonged sitting has a negative impact on peripheral and central vascular health, particularly on leg vasodilatory function and aortic pulse wave velocity.

Negative effect of periodontitis on antihypertensive treatment success at high BP

Nov. 1, 2018 - Pietropaoli D et al. - Hypertension 2018

A retrospective study showed better SBP during antihypertensive therapy and lower risk of antihypertensive treatment failure in hypertensive patients with good oral health, as compared with those with periodontitis.

No increased risk of congenital overall or cardiac malformations with the use of β-blockers in early pregnancy

Nov. 1, 2018 - Bateman BT et al. - Annals of Internal Medicine 2018

In a cohort study, use of β-blockers in the first trimester was not associated with increased risk of congenital overall or cardiac malformations.